Dexcom Hit With Class Action Over Faulty Glucose Monitors

0
59
Dexcom Glucose Monitor Tech

A proposed class of consumers has launched a lawsuit against Dexcom Inc., accusing the medical device maker of misleading advertising and dangerous product defects tied to its popular G7 Continuous Glucose Monitoring (CGM) System — a device marketed as the “most accurate” glucose tracker approved by the U.S. Food and Drug Administration (FDA).

The complaint, filed Wednesday by Kelly Grisoli, alleges that Dexcom falsely assured users its monitors were safe and dependable, even as the FDA issued multiple Class I recalls — the agency’s most serious warning level, reserved for defects that can cause severe injury or death.

Recalls, Hidden Design Changes, and Mounting Complaints

According to the lawsuit, Dexcom quietly altered the sensor material in its G7 system in December 2023 without prior FDA approval. The unapproved change allegedly degraded the device’s accuracy, making readings unreliable and potentially life-threatening for diabetics who depend on the monitor to regulate their blood sugar.

Signup for the USA Herald exclusive Newsletter

Grisoli, who purchased the device for her diabetic son, said she quickly noticed defects. The sensors often failed before the promised 10-day lifespan, triggering false glucose readings and repeated hypoglycemic or hyperglycemic episodes. The complaint cites reports that at least one user died after a failed sensor falsely showed “normal” glucose levels.

Despite the malfunctions, Dexcom continued to promote the G7 as the gold standard in glucose tracking, claiming precision and safety unmatched by competitors. Grisoli contends those assurances were misleading — especially in light of FDA inspection findings that Dexcom had no adequate quality control procedures and had improperly implemented the design change.